A Multi-Center, Parallel-Group, Randomized, Double Blind, Adaptive Study Investigating the Safety and Efficacy of THR-184 in Patients at Increased Risk of Developing Cardiac Surgery Associated-Acute Kidney Injury (CSA-AKI)
Phase of Trial: Phase II
Latest Information Update: 25 Apr 2017
At a glance
- Drugs THR 184 (Primary)
- Indications Acute kidney injury
- Focus Therapeutic Use
- Sponsors Thrasos Therapeutics
- 29 Feb 2016 According to a Thrasos Therapeutics media release, full results of this study will be submitted for presentation at an upcoming scientific conference.
- 29 Feb 2016 Top-line results published in a Thrasos Therapeutics media release.
- 29 Feb 2016 According to a Thrasos Therapeutics media release, status changed from active, no longer recruiting to completed.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History